Therefore, a preponderance of evidence supports a role for SGLT2 inhibitors in preserving NO bioavailability and endothelial function in diabetes by influencing the activity or expression of numerous molecules that impact eNOS, oxidative stress, inflammation, vascular reactivity, and blood pressure. The gene discussed is SLC5A2; the disease is diabetes mellitus.